The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for inducing weight loss has increased in recent years, resulting in a parallel reduction in demand for bariatric surgery. Consequently, the need for patients to undergo aesthetic procedures, including aesthetic breast surgery, following successful GLP-1 RA–induced weight loss is expected to increase while the demand created by postsurgical weight loss is expected to decrease. The objective of this narrative review is to examine the literature on the use of GLP-1 RAs and other mechanisms used for medical weight loss to assist plastic surgeons in achieving optimal aesthetic outcomes with breast surgery after weight loss occurs.

Recurrent herpes labialis (RHL) is a common condition characterized by episodic viral reactivation triggered by local or systemic factors. Hyaluronic acid (HA) lip augmentation is widely performed for aesthetic purposes, yet its potential association with changes in herpes labialis recurrence has not been systematically evaluated. The aim of this study was to investigate whether repeated lip augmentation with HA filler is associated with changes in the incidence of RHL episodes over time.

Hyaluronic acid (HA) is widely used for lip augmentation; however, the safety and performance of injection techniques and instruments (needle vs cannula) remain unclear. The aim of this study was to evaluate the safety of HA injection techniques for lip augmentation and to assess patient satisfaction, injected volume, and associations with technique, instrument, and HA product.

Nonsurgical aesthetic treatments have been found to improve patient confidence; however, the interplay between patient attitudes and aesthetic treatment experiences is not fully understood. The aim of this study was to further characterize the role of confidence and self-perception in the decision to pursue aesthetic treatments and in patient experience of outcomes.

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.